Mission Therapeutics is a world leader in deubiquitylating enzyme (DUB) drug discovery and development, leveraging a proprietary platform to identify selective DUB inhibitors. Its lead programs, MTX325 and MTX652, target USP30 to enhance mitophagy and are in clinical development for Parkinson's disease and other conditions. The company is privately held, has raised significant capital and non-dilutive funding, and advances its pipeline through in-house development and strategic partnerships.
World-leading deubiquitylating enzyme (DUB) drug discovery platform for identifying and developing selective small molecule inhibitors against disease-associated DUBs, with deep expertise in ubiquitin pathway biology, screening, and medicinal chemistry.
Funding History
3
Total raised:$174M
Series C$68MPfizer Venture Investments
Series B$86MNovo Holdings
Series A$20MSR One
Opportunities
The lead USP30 inhibitor program addresses the vast, unmet need for disease-modifying therapies in Parkinson's disease, a multi-billion dollar market.
Furthermore, the platform's mechanism of enhancing mitophagy has broad applicability across neurodegenerative, fibrotic, renal, and cardiac diseases, enabling pipeline expansion into multiple large therapeutic areas.
Risk Factors
The company faces high clinical risk as its first-in-class DUB inhibitors have unproven efficacy and safety in patients.
It is also dependent on securing future financing to advance its pipeline and relies on forming successful partnerships for later-stage development and commercialization.
Competitive Landscape
Mission is a recognized leader in the specialized DUB inhibitor field, but faces competition from other companies targeting mitophagy and protein homeostasis for neurodegenerative diseases. In Parkinson's disease, it competes with both symptomatic treatments and other novel disease-modifying approaches in development by larger biopharma firms.
